Afrigen Biologics (Pty) Ltd

Afrigen Biologics and Vaccines is a Cape Town based biotechnology company strategically directed, supported and capitalized by Avacare Healthcare Group and the Industrial Development Corporation (IDC) of South Africa. It was founded in 2014 by Steven G. Reed (PhD) and Erik Iverson (JD, LLM), both of the Infectious Diseases Research Institute (IDRI) in Seattle. Afrigen drives a business strategy focussing on product development, bulk adjuvant manufacturing, and supply and distribution of key biologicals to address unmet healthcare needs. Through international partnerships and local capacity building, Afrigen has established the first ever adjuvant production and formulation technology centre on the African continent. This centre, in partnership with IDRI, a world leader in adjuvant development, focuses on next generation vaccine adjuvants, which are not only geared at preventing disease, but have therapeutic value. These adjuvants confer added potency and durability to vaccines. MISSION Afrigen is dedicated to the local development and production of adjuvants for human and animal vaccines, as well as biologicals critical for Africa’s healthcare challenges. PLEASE VIEW OUR PRIVACY STATEMENT & DISCLAIMERS HERE: https://www.afrigen.co.za/privacy-statement/ https://www.afrigen.co.za/disclaimers/